(Updated - October 27, 2014 4:03 PM EDT)

Amgen (NASDAQ: AMGN) reported Q3 EPS of $2.30, $0.19 better than the analyst estimate of $2.11. Revenue for the quarter came in at $5.03 billion versus the consensus estimate of $4.96 billion..

Product Sales Performance

• Total product sales increased 4 percent for the third quarter of 2014 versus the third quarter of 2013. The increase was mainly driven by Kyprolis, Prolia, Neulasta and XGEVA. Growth for the quarter was primarily due to unit demand and, to a lesser extent, price.
• Kyprolis sales for the third quarter of 2014 were $94 million, a 21 percent increase quarter-over-quarter, driven by higher unit demand.
• Prolia sales increased 43 percent year-over-year driven by higher unit demand from share growth.
• Neulasta sales increased 5 percent year-over-year driven mainly by price. Global NEUPOGEN sales decreased 36 percent year-over-year mainly due to a $155 million order from the U.S. government in the third quarter of 2013. Underlying demand for both products was slightly impacted by competition.
• XGEVA sales increased 22 percent year-over-year driven by higher unit demand. XGEVA continues to capture share in a growing market in the face of competition from generic zoledronic acid.
• Vectibix® (panitumumab) sales increased 29 percent year-over-year driven by higher unit demand across all regions. In the U.S., Vectibix received Food and Drug Administration (FDA) approval at the end of the second quarter of 2014 for first-line treatment in combination with FOLFOX for patients with wild-type KRAS metastatic colorectal cancer.
• EPOGEN® (epoetin alfa) sales increased 5 percent year-over-year driven by price. Unit demand continues to be relatively stable.
• Aranesp® (darbepoetin alfa) sales increased 6 percent year-over-year driven largely by unit demand in international markets.
• ENBREL realized unit growth of 3 percent year-over-year. This partially offset unfavorable changes in inventory resulting in a 3 percent decrease year-over-year in product sales.
• Sensipar®/Mimpara® (cinacalcet) sales increased 5 percent year-over-year driven primarily by increases in unit demand.
• Nplate® (romiplostim) increased 12 percent year-over-year driven mainly by higher unit demand and strong market growth across all regions.

For the full year 2014, the Company expects:

• Total revenues to be in the range of $19.8 billion to $20.0 billion and adjusted EPS to be in the range of $8.45 to $8.55. (The Street is at revenue of $19.7 billion and EPS of $8.42.)

For earnings history and earnings-related data on Amgen (AMGN) click here.